Ligand Pharmaceuticals (LGND) opened Q1 2026 with revenue of US$51.7 million and a basic EPS loss of US$0.67, alongside a net loss of US$13.3 million. The company reported revenue of US$45.3 million and a basic EPS loss of US$2.21 in Q1 2025, compared with US$51.7 million and a basic EPS loss of US$0.67 in Q1 2026. Trailing twelve month EPS stood at US$7.87 on net income of US$153.6 million. For investors, the combination of a quarterly loss and a profitable trailing year encourages a closer look at how margins are holding up during this period.

See our full analysis for Ligand Pharmaceuticals.

With the headline figures on the table, the next step is to see how these results align with the main narratives around Ligand's growth, profitability, and risk profile, and where the numbers may present a different perspective.

Trailing US$153.6m profit set against recent Q1 loss

• Over the last 12 months, Ligand generated trailing revenue of US$274.5 million and net income of US$153.6 million, even though Q1 2026 itself showed a net loss of US$13.3 million on revenue of US$51.7 million.
• For a bullish view, what stands out is that the recent move into profitability on a trailing basis sits beside earlier quarters with losses, with trailing basic EPS at US$7.87 compared with a Q1 2026 basic EPS loss of US$0.67. This supports the idea that earnings power is now more visible, but also highlights that quarter to quarter swings are still meaningful.
  • Supporters pointing to a return to profit over the last year can reference the shift from a Q1 2025 net loss of US$42.5 million to positive trailing net income of US$153.6 million.
  • At the same time, the presence of loss making quarters like Q1 2026 means bulls still have to account for earnings volatility when thinking about how consistent that trailing profit base may be.

With profitability only recently showing up on a trailing basis and quarterly swings still in play, many investors look for a fuller story that connects the numbers to longer term expectations and risks through community views and deeper analysis of the business model and pipeline: Curious how numbers become stories that shape markets? Explore Community Narratives.

Revenue up to US$51.7m versus US$42.8m in late 2024

• Q1 2026 revenue of US$51.7 million compares with US$42.8 million in Q4 2024 and sits within a trailing twelve month revenue base of US$274.5 million, which includes periods with much higher quarterly revenue such as US$115.5 million in Q3 2025.
• Critics taking a more cautious view will notice that this revenue path and the earnings pattern include both strong profit quarters, like Q3 2025 net income of US$117.3 million, and loss making periods, like Q1 2025 and Q4 2024. This challenges a simple bullish narrative that recent profitability alone resolves the five year record of earnings declining at about 2.5% per year.
  • The presence of multiple quarters with net losses, including Q1 2025 with a loss of US$42.5 million and Q4 2024 with a loss of US$31.1 million, contrasts with the strong trailing net income of US$153.6 million.
  • This mix of outcomes means any bullish focus on recent profit has to be weighed against the fact that earnings over the last five years have declined by about 2.5% annually, so the longer term pattern is more mixed.

P/E of 27.4x versus 16.7x industry and US$377.7 DCF fair value

• The stock trades on a trailing P/E of 27.4x compared with the US Pharmaceuticals industry average of 16.7x and sits against a DCF fair value estimate of US$377.68 and an analyst target of US$269.80, versus a current share price of US$210.33.
• For investors weighing a bullish case, one point of interest is that the higher than industry P/E and the five year earnings decline of about 2.5% per year sit alongside forecasts for roughly 16% annual earnings growth and 15.4% annual revenue growth. This creates a clear tension between past trends and forward looking expectations.
  • The valuation metrics imply the stock trades below both the DCF fair value estimate of US$377.68 and the analyst target of US$269.80, even though the P/E is higher than the broader industry average.
  • Forecast revenue growth of about 15.4% per year compares with a broader US market revenue forecast of 11.4% per year, which supports the idea that the company’s growth outlook is stronger than the wider market despite its mixed multi year earnings record.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Ligand Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seen enough to sense the market’s mixed mood around Ligand, but still on the fence? Take a closer look at the underlying drivers and judge how the risk reward trade off looks to you by reviewing the 4 key rewards

See What Else Is Out There

Ligand's mix of quarterly losses, earnings volatility, and a higher than industry P/E against a multi year earnings decline suggests the risk reward profile is uneven.

If that patchy record makes you cautious, compare it with companies that score better on stability and downside protection by checking out the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.